Fairmount Funds Sells $133.5M Stake in Apogee Therapeutics
Apogee Therapeutics stock drops 12% after major investor Fairmount Funds Management sells 1.75 million shares worth $133.5 million, significantly reducing its position.
Feed↓
/ What's going on?
Filter:
Microsoft Earnings Preview: Wall Street Optimistic Despite Price Target Cuts
Wall Street analysts remain bullish on Microsoft ahead of earnings but trim price targets amid software sector selloff. Azure growth and AI adoption remain key focus areas.
California Sues Trump Administration Over Oil Pipeline Authority
California Attorney General Rob Bonta files lawsuit against Trump administration for reclassifying state pipelines as interstate to permit Sable Offshore oil operations.
Sigma Lithium Secures Major Sale Amid Media Controversy
Sigma Lithium sells 100,000 tonnes of lithium fines at premium prices while denying false media reports about operational shutdowns and addressing defamation campaign.
Leerink Upgrades Relmada Therapeutics With $8 Price Target
Leerink starts coverage on Relmada Therapeutics, upgrades the stock to Outperform, and highlights strong potential for its bladder cancer program NDV-01.
Bausch Health’s Liver Drug Fails in Late-Stage Trials
Bausch Health said its experimental liver treatment did not meet goals in Phase 3 trials, sending shares lower in early trading.